NCT06683014View on ClinicalTrials.gov

MDMA in Borderline Personality Disorder

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 5, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Borderline Personality Disorder
Interventions
DRUG

MDMA

Participants will receive one dose of open-label 3,4-methylenedioxymethamphetamine (MDMA).

Trial Locations (1)

06519

RECRUITING

Connecticut Mental Health Center, New Haven

All Listed Sponsors
collaborator

Connecticut Mental Health Center

UNKNOWN

lead

Yale University

OTHER

NCT06683014 - MDMA in Borderline Personality Disorder | Biotech Hunter | Biotech Hunter